BAYS F BARRY
Known title: DirectorCIK: 0001183554
Associated companies
Transaction History
| TMCI | ▼ Sell | Open Market | 1,042,318 | $27.6M | 6/5/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 48,503 | $1.3M | 6/2/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 11,600 | $294K | 4/27/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 16,204 | $414K | 4/26/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 36,370 | $950K | 4/12/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 44,764 | $1.2M | 4/11/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 5,026 | $137K | 4/11/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 32,457 | $820K | 3/29/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 26,241 | $657K | 3/28/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 9,400 | $219K | 3/14/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 8,320 | $200K | 3/13/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 1,080 | $27K | 3/13/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 9,400 | $207K | 2/22/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 9,400 | $204K | 2/21/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 27,731 | $602K | 2/8/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 8,800 | $202K | 2/7/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 20,467 | $517K | 1/25/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 7,255 | $187K | 1/25/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 25,921 | $675K | 1/24/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 23,695 | $596K | 1/12/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 21,841 | $567K | 1/12/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 9,719 | $236K | 1/11/2023 | View on chart |
| TMCI | ▼ Sell | Open Market | 9,414 | $219K | 12/20/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 9,067 | $207K | 12/19/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 9,739 | $234K | 12/8/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 9,061 | $217K | 12/7/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 9,400 | $208K | 11/29/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 9,400 | $208K | 11/28/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 1,500 | $34K | 11/10/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 7,900 | $187K | 11/10/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 4,100 | $85K | 11/9/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 13,023 | $276K | 11/9/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 615 | $14K | 10/19/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 25,647 | $583K | 10/19/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 25,428 | $611K | 10/18/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 13,500 | $313K | 10/6/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 16,274 | $367K | 10/5/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 23,068 | $531K | 9/28/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 14,424 | $322K | 9/27/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 13,836 | $317K | 9/14/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 9,746 | $235K | 9/14/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 25,075 | $592K | 9/14/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 19,700 | $442K | 9/13/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 3,800 | $77K | 8/30/2022 | View on chart |
| TMCI | ▼ Sell | Open Market | 8,064 | $162K | 8/29/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Treace Medical Shares Five-Year Bunion Study Results
Treace Medical Concepts published five-year clinical results for its bunion treatment, aiming to strengthen evidence for broader adoption. This scientific update provides context for the stock's current position, which is trading near a key support level and below the average analyst price target.
Treace Medical Shares Five-Year Bunion Study Results. Treace Medical Concepts published five-year clinical results for its bunion treatment, aiming to strengthen evidence for broader adoption. This scientific update provides context for the stock's current position, which is trading near a key support level and below the average analyst price target.